Publications by authors named "Matthew A Held"

Claim this Profile
P
Phospho-PTM proteomic discovery of novel EPO- modulated kinases and phosphatases, including PTPN18 as a positive regulator of EPOR/JAK2 Signaling.
Matthew A Held, Emily Greenfest-Allen, Su Su, Christian J Stoeckert, Matthew P Stokes

Cell Signal· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phospho-proteomic discovery of novel signal transducers including thioredoxin-interacting protein as mediators of erythropoietin-dependent human erythropoiesis.
Matthew A Held, Emily Greenfest-Allen, Edward Jachimowicz, Christian J Stoeckert, Matthew P Stokes

Exp Hematol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combinatorial drug screening of mammary cells with induced mesenchymal transformation to identify drug combinations for triple-negative breast cancer.
Sierra A Colavito, James T Platt, Matthew A Held, Zongzhi Liu, Ryan Sokup

Oncotarget· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing Workflows for LC/MS Analysis of Co-Immunoprecipitated Protein Complexes - "Soap Opera(tions)".
Matthew A Held, Don M Wojchowski

J Proteomics Bioinform· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.
David P Kodack, Anna F Farago, Anahita Dastur, Matthew A Held, Leila Dardaei

Cell Rep· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor.
Casey G Langdon, James T Platt, Robert E Means, Pinar Iyidogan, Ramanaiah Mamillapalli, Matthew A Held

Mol Cancer Ther· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.
Vikram B Wali, Casey G Langdon, Matthew A Held, James T Platt, Gauri A Patwardhan

Cancer Res· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.
Casey G Langdon, Norbert Wiedemann, Matthew A Held, Ramanaiah Mamillapalli, Pinar Iyidogan

Oncotarget· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.
Casey G Langdon, Matthew A Held, James T Platt, Katrina Meeth, Pinar Iyidogan

Pigment Cell Melanoma Res· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume.
Nicholas Theodosakis, Matthew A Held, Alexander Marzuka-Alcala, Katrina M Meeth, Goran Micevic

Mol Cancer Ther· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genotype-selective combination therapies for melanoma identified by high-throughput drug screening.
Matthew A Held, Casey G Langdon, James T Platt, Tisheeka Graham-Steed, Zongzhi Liu

Cancer Discov· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isolation of total RNA from transgenic mouse melanoma subsets using fluorescence-activated cell sorting.
Scott Tighe, Matthew A Held

Methods Mol Biol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of melanoma cells capable of propagating tumors from a single cell.
Matthew A Held, David P Curley, David Dankort, Martin McMahon, Viswanathan Muthusamy

Cancer Res· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alterations in growth hormone receptor abundance regulate growth hormone signaling in murine obstructive cholestasis.
Matthew A Held, Wilfredo Cosme-Blanco, Lisa M Difedele, Erin L Bonkowski, Ram K Menon

Am J Physiol Gastrointest Liver Physiol· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor necrosis factor alpha blockade restores growth hormone signaling in murine colitis.
Lisa M DiFedele, Jiman He, Erin L Bonkowski, Xiaonan Han, Matthew A Held

Gastroenterology· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis.
Alan Bohan, Wen-Sheng Chen, Lee A Denson, Matthew A Held, James L Boyer

J Biol Chem· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-6 inhibits hepatic growth hormone signaling via upregulation of Cis and Socs-3.
Lee A Denson, Matthew A Held, Ram K Menon, Stuart J Frank, Albert F Parlow

Am J Physiol Gastrointest Liver Physiol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Organ-specific alterations in RAR alpha:RXR alpha abundance regulate rat Mrp2 (Abcc2) expression in obstructive cholestasis.
Lee A Denson, Alan Bohan, Matthew A Held, James L Boyer

Gastroenterology· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis